Blog

Justin Stebbing: Excited to be a communicating author with benefits to patients with “cold tumours”

Justin Stebbing/healthpost.in

Jul 4, 2024, 15:34

Justin Stebbing: Excited to be a communicating author with benefits to patients with “cold tumours”

“Really excited to be part of this/communicating author with benefits to patients with ‘cold tumours’.”

Source:

Justin Stebbing: Excited to be a communicating author with benefits to patients with "cold tumours"

Justin Stebbing is a visiting Professor of Cancer Medicine and Oncology at Imperial College, London and a Professor of Biomedical Sciences at Anglia Ruskin University (ARU), Cambridge. He was appointed the first NIHR oncology professor in 2011. He is editor-in-chief of Nature’s cancer journal Oncogene. Prof. Stebbing has published over 700 peer-reviewed papers in leading academic journals. He is a member of the American Society for Clinical Investigation, a fellow of the Royal College of Physicians, and the Royal College of Pathologists, and sits on many advisory boards. He is on the Editorial Board of OncoDaily.

Anglia Ruskin University botensilimab plus balstilimab cancer cold tumours communicating author Imperial College Justin Stebbing OncoDaily Oncology Research

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer